A Phase 1 interventional study of LY2189265 and Sitagliptin in Diabetes Mellitus, Type 2, sponsored by Eli Lilly and Company. Completed at 3 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2014-10-07.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 — 3 open to participants now, 4 under way, 1 of them phase 3. dulaglutide · Diabetes Mellitus, Type 2.
Among the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, this one is the 48th largest by enrollment, is one of 8 that started in 2011, is one of 15 in phase 1, and was the 16th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States, Argentina, Mexico
Ages 10–17
First Affiliated Hospital of Wannan Medical College
Ages 18+
Seoul National University Bundang Hospital
Ages 20–90
By country, each count listing its studies:
dulaglutide: first FDA approval 2014 (TRULICITY), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 6 · Phase 3 23 · Phase 4 9
First in 2008; this study’s year is marked. 8 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 29 is below the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 159 across the 54 interventional studies. Of the 47 that completed or were terminated, 38 (81%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 54 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company: 10 open now, 21 under way, 11 of them phase 3. Of 211 finished, 155 (73%) have results posted.
Among the 238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company, this one is the 207th largest by enrollment of the 232 interventional ones that give a count, is one of 22 that started in 2011, is one of 76 in phase 1, and was the 68th registered.
Eli Lilly and Company’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
1 of the studies testing dulaglutide in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07537088First Affiliated Hospital of Wannan Medical CollegeEfficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney Disease | 2027-04 |
Add it to your calendar (.ics) → With an account.
Among the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 238 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to study the effect of LY2189265 on how the body absorbs and processes a Type 2 Diabetes Mellitus (T2DM) drug (sitagliptin) and how sitagliptin affects LY2189265 when they are taken together.
The duration of participation in this study is expected to be approximately 61 days. The study requires 2 clinic confinements (one of 2 nights and one of 19 nights duration).
The study involves 3 injections, subcutaneous, of 1.5 milligrams (mg) LY2189265 and 18 daily doses of 100 mg sitagliptin tablets administered orally.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
male participants with female partners of , or partners who are pregnant or breastfeeding, agree to use a reliable method of from the time of the first dose until 3 months after the last dose of product, as determined by the investigator. The method may be one of the following:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A single 1.5-milligram (mg) dose of LY2189265 administered subcutaneously (Treatment 1). There was a washout period of at least 21 days before crossing over and receiving 100 mg of sitagliptin administered orally, once daily for 18 days in combination with two separate single 1.5-mg doses of LY2189265 administered subcutaneously, immediately prior to the sitagliptin doses on Day 5 and Day 12 (Treatment 2).
Biological: LY2189265 · Drug: Sitagliptin
100 mg of sitagliptin administered orally, once daily for 18 days in combination with two separate single 1.5-mg doses of LY2189265 administered subcutaneously, immediately prior to the sitagliptin doses on Day 5 and Day 12 (Treatment 2). There was a washout of at least 21 days before crossing over and receiving a single 1.5 mg dose of LY2189265 administered subcutaneously (Treatment 1).
Biological: LY2189265 · Drug: Sitagliptin
Administered subcutaneously
Also known as: Dulaglutide
Administered orally
Pharmacokinetics: Area Under the Concentration Versus Time Curve (AUC) of Sitagliptin
Area under the sitagliptin pharmacokinetic (PK) concentration versus time curve (AUC \[0-tau\]) during one dosing interval (24 hours) is summarized.
Time frame: Predose and up to 24 hours postdose on Day 4, Day 6, and Day 13 of Treatment 2
Pharmacokinetics: Maximum Observed Drug Concentration (Cmax) of Sitagliptin
Time frame: Predose and up to 24 hours postdose on Day 4, Day 6, and Day 13 of Treatment 2
Pharmacokinetics: Time of Maximum Observed Drug Concentration (Tmax) of Sitagliptin
Time frame: Predose and up to 24 hours post dose on Day 4, Day 6, and Day 13 of Treatment 2
Pharmacokinetics: Area Under the Concentration Versus Time Curve (AUC) of LY2189265
Area under the LY2189265 pharmacokinetic (PK) concentration versus time curve (AUC \[0-tau\]) during one dosing interval (168 hours) is summarized.
Time frame: Predose and up to 168 hours postdose on Day 1 of Treatment 1 and on Day 5 and Day 12 of Treatment 2
Pharmacokinetics: Maximum Observed Drug Concentration (Cmax) of LY2189265
Time frame: Predose and up to 168 hours postdose on Day 1 of Treatment 1 and on Day 5 and Day 12 of Treatment 2
Pharmacokinetics: Time of Maximum Observed Drug Concentration (Tmax) of LY2189265
Time frame: Predose and up to 168 hours postdose on Day 1 of Treatment 1 and on Day 5 and Day 12 of Treatment 2
| Milestone | LY2189265, Sitagliptin + LY2189265 | Sitagliptin + LY2189265, LY2189265 |
|---|---|---|
| Started | 18 | 11 |
| Received at least 1 dose of drug | 18 | 11 |
| Completed | 18 | 8 |
| Not completed | 0 | 3 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 2 |
| Milestone | LY2189265, Sitagliptin + LY2189265 | Sitagliptin + LY2189265, LY2189265 |
|---|---|---|
| Started | 18 | 8 |
| Completed | 18 | 8 |
| Not completed | 0 | 0 |
| Milestone | LY2189265, Sitagliptin + LY2189265 | Sitagliptin + LY2189265, LY2189265 |
|---|---|---|
| Started | 18 | 8 |
| Completed | 16 | 8 |
| Not completed | 2 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 |
| Withdrew: Adverse event | 1 | 0 |
Area under the sitagliptin pharmacokinetic (PK) concentration versus time curve (AUC \[0-tau\]) during one dosing interval (24 hours) is summarized.
| nanograms times hour/milliliter(ng*h/mL) | 100 mg Sitagliptin (Day 4) | 100 mg Sitagliptin + 1.5 mg LY2189265 (Day 6) | 100 mg Sitagliptin + 1.5 mg LY2189265 (Day 13) |
|---|---|---|---|
| Pharmacokinetics: Area Under the Concentration Versus Time Curve (AUC) of Sitagliptin | 3210 ± 34 | 3240 ± 36 | 2970 ± 54 |
| nanograms/milliliter (ng/mL) | 100 mg Sitagliptin (Day 4) | 100 mg Sitagliptin + 1.5 mg LY2189265 (Day 6) | 100 mg Sitagliptin + 1.5 mg LY2189265 (Day 13) |
|---|---|---|---|
| Pharmacokinetics: Maximum Observed Drug Concentration (Cmax) of Sitagliptin | 417 ± 46 | 374 ± 61 | 318 ± 77 |
| hours | 100 mg Sitagliptin (Day 4) | 100 mg Sitagliptin + 1.5 mg LY2189265 (Day 6) | 100 mg Sitagliptin + 1.5 mg LY2189265 (Day 13) |
|---|---|---|---|
| Pharmacokinetics: Time of Maximum Observed Drug Concentration (Tmax) of Sitagliptin | 1.00 (0.500 to 4.00) | 2.00 (0.500 to 16.0) | 2.00 (0.500 to 12.0) |
Area under the LY2189265 pharmacokinetic (PK) concentration versus time curve (AUC \[0-tau\]) during one dosing interval (168 hours) is summarized.
| nanograms times hour/milliliter(ng*h/mL) | 1.5 mg LY2189265 (Day 1) | 100 mg Sitagliptin + 1.5 mg LY2189265 (Day 5) | 100 mg Sitagliptin + 1.5 mg LY2189265 (Day 12) |
|---|---|---|---|
| Pharmacokinetics: Area Under the Concentration Versus Time Curve (AUC) of LY2189265 | 6590 ± 40 | 8890 ± 26 | 13900 ± 26 |
| nanograms/milliliter (ng/mL) | 1.5 mg LY2189265 (Day 1) | 100 mg Sitagliptin + 1.5 mg LY2189265 (Day 5) | 100 mg Sitagliptin + 1.5 mg LY2189265 (Day 12) |
|---|---|---|---|
| Pharmacokinetics: Maximum Observed Drug Concentration (Cmax) of LY2189265 | 52.9 ± 37 | 68.1 ± 25 | 101 ± 28 |
| hours | 1.5 mg LY2189265 (Day 1) | 100 mg Sitagliptin + 1.5 mg LY2189265 (Day 5) | 100 mg Sitagliptin + 1.5 mg LY2189265 (Day 12) |
|---|---|---|---|
| Pharmacokinetics: Time of Maximum Observed Drug Concentration (Tmax) of LY2189265 | 72.0 (12.0 to 120) | 72.0 (48.0 to 144) | 59.8 (12.0 to 120) |
Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| LY2189265 | — | 0/26 (0%) | 11/26 (42.3%) |
| Sitagliptin | — | 0/29 (0%) | 10/29 (34.5%) |
| Sitagliptin + LY2189265 | — | 2/29 (6.9%) | 16/29 (55.2%) |
| Event | LY2189265 | Sitagliptin | Sitagliptin + LY2189265 |
|---|---|---|---|
| Pneumonia bacterialInfections and infestations | 0/26 | 0/29 | 1/29 |
| ConcussionInjury, poisoning and procedural complications | 0/26 | 0/29 | 1/29 |
| Renal failure acuteRenal and urinary disorders | 0/26 | 0/29 | 1/29 |
| Event | LY2189265 | Sitagliptin | Sitagliptin + LY2189265 |
|---|---|---|---|
| HeadacheNervous system disorders | 4/26 | 1/29 | 5/29 |
| NauseaGastrointestinal disorders | 1/26 | 0/29 | 4/29 |
| Decreased appetiteMetabolism and nutrition disorders | 1/26 | 0/29 | 4/29 |
| HypoglycaemiaMetabolism and nutrition disorders | 1/26 | 1/29 | 4/29 |
| FatigueGeneral disorders | 3/26 | 1/29 | 2/29 |
| Abdominal discomfortGastrointestinal disorders | 2/26 | 0/29 | 0/29 |
| DyspepsiaGastrointestinal disorders | 2/26 | 0/29 | 1/29 |
| Injection site painGeneral disorders | 2/26 | 0/29 | 1/29 |
| Abdominal painGastrointestinal disorders | 0/26 | 0/29 | 2/29 |
| DiarrhoeaGastrointestinal disorders | 1/26 | 0/29 | 2/29 |
Participants who received at least one dose of study drug (LY2189265 or Sitagliptin).
| Age, Continuous(years) | Entire Study Population |
|---|---|
| Mean | 52.7 ± 11.1 |
| Sex: Female, Male(Participants) | Entire Study Population |
|---|---|
| Female | 10 |
| Male | 19 |
| Ethnicity (NIH/OMB)(Participants) | Entire Study Population |
|---|---|
| Hispanic or Latino | 5 |
| Not Hispanic or Latino | 24 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Entire Study Population |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 4 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 14 |
| White | 11 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | Entire Study Population |
|---|---|
| United States | 29 |
The record gives a start of Aug 2011, a primary completion of Apr 2012 and a completion of Apr 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2014, 2 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dulaglutide